^
    Back
    Association details:
    Biomarker:EGFR amplification
    Cancer:Non Small Cell Lung Cancer
    Drug:Tagrisso (osimertinib) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    J Cancer Res Clin Oncol
    Title:

    Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes

    Published date:
    05/10/2020
    Excerpt:
    We retrospectively analyzed patients with advanced NSCLC who received osimertinib....In patients who developed resistance to osimertinib, possible genomic resistance mutations were identified in 27 of 49 patients in the molecular analysis set...Other EGFR-dependent molecular modifications included C796S mutation (1/49, 2.0%), G796S mutation (1/49, 2.0%), V802I mutation (1/49, 2.0%), V834L mutation (1/49, 2.0%), E758D mutation (1/49, 2.0%), G724S mutation (1/49, 2.0%) and EGFR amplification (2/49, 4.1%)...A summary of resistance mechanisms to osimertinib are shown in Fig. 2.
    DOI:
    10.1007/s00432-020-03239-1
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    Transl Lung Cancer Res
    Title:

    ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib

    Published date:
    03/13/2020
    Excerpt:
    Table 2 Molecular alterations detected in ctDNA upon progression to osimertinib treatment
    DOI:
    10.21037/tlcr.2020.04.01